Headlines about SteadyMed (NASDAQ:STDY) have trended positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SteadyMed earned a news impact score of 0.44 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.1625587187764 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Separately, Zacks Investment Research upgraded SteadyMed from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th.

Shares of SteadyMed (NASDAQ:STDY) traded down 1.61% during trading on Tuesday, hitting $6.10. The stock had a trading volume of 10,595 shares. SteadyMed has a 1-year low of $2.25 and a 1-year high of $9.70. The stock’s 50-day moving average price is $6.49 and its 200 day moving average price is $5.43. The firm’s market capitalization is $153.54 million.

COPYRIGHT VIOLATION WARNING: This piece was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/08/steadymed-nasdaqstdy-receiving-favorable-news-coverage-study-finds.html.

About SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH).

Insider Buying and Selling by Quarter for SteadyMed (NASDAQ:STDY)

Receive News & Ratings for SteadyMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SteadyMed Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.